Search results
- Regulatory news (469) Apply Regulatory news filter
- Press releases (244) Apply Press releases filter
- Basic page (60) Apply Basic page filter
- Corporate presentations (29) Apply Corporate presentations filter
- Pipeline (26) Apply Pipeline filter
- Shareholder meeting (24) Apply Shareholder meeting filter
- Team member (22) Apply Team member filter
- Videos (16) Apply Videos filter
- Webcasts and audio (14) Apply Webcasts and audio filter
- Financial reports (13) Apply Financial reports filter
- Analyst (11) Apply Analyst filter
- Investor contact (5) Apply Investor contact filter
- Event (4) Apply Event filter
- Research (3) Apply Research filter
- Financial calendar (1) Apply Financial calendar filter
- Webform (1) Apply Webform filter
2021 Annual report and accounts & AGM notification
London, UK – 27 April 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, “the Company” or “the Group”), a leading gene and
Oxford Biomedica Solutions announces novel Dual Plasmid Transfection System, and has demonstrated suspension bioreactor titers above E15 vg/L, and chromatography purification achieving 90% fully in-tact vector
Bedford, Massachusetts - May 6, 2022: Oxford Biomedica Solutions, LLC.
TCR-T (Immatics)
This is a partner programme. Visit the Immatics website for further information.
CAR-T (Arcellx)
This is a partenr programme. Visit the Arcellx website for more information.
Oxford Biomedica notes announcement that FDA has lifted clinical hold on Homology Medicines’ pheNIX trial
Oxford, UK – 14 June 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy g
Oxford Biomedica signs new three year agreement with AstraZeneca
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse